Taxanes are a mainstay of chemotherapy for gynecologic malignancies. Anecdotally, the rate of taxane hypersensitivity reactions (HSRs) has risen at our institution over the past several years. Titration, or slowing the rate, of taxanes is the primary treatment for HSRs. Our institution implemented a universal titration protocol for all patients receiving a taxane to attempt to decrease the number of HSRs. The primary aim of this study is to determine if use of this protocol at time of taxane administration reduced the rate of HSRs.

A retrospective review was performed of gynecologic oncology patients (pts) who received taxane before or after implementation of a titration protocol in February 2024. A 12-month period was used for each cohort of pts. Pts were excluded if they received treatment both before and after implementation of the protocol, or if they received a taxane in a prior line of treatment. A Fisher’s exact test was used to compare HSR rates, grades of reaction, rates of ED presentations, and admission rates in each group.

Data collection ongoing